中慧生物
Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

(I) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER
(II) NOMINATION OF EXECUTIVE DIRECTORS
(III) APPOINTMENT OF CHIEF FINANCIAL OFFICER
(IV) CHANGE OF MEMBERS OF BOARD COMMITTEES
(V) APPOINTMENT OF BOARD SECRETARY AND JOINT COMPANY SECRETARY
(VI) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
(VII) CHANGE OF AUTHORIZED REPRESENTATIVE
AND
(VIII) CONTINUED SUSPENSION OF TRADING

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

The board (the "**Board**") of directors (the "**Directors**") of Ab&B Bio-Tech CO., LTD. JS (the "**Company**", together with its subsidiary, the "**Group**") hereby announces that, due to adjustment of work arrangements, Ms. LI Runxiang (李潤香) ("**Ms. Li**") has tendered her resignation to the Board as, among others, an executive Director and the chief financial officer of the Company (the "**Chief Financial Officer**"), with effect from September 23, 2026.

Ms. Li has confirmed that she has no disagreement with the Board and that there is no matter in respect of her resignation which needs to be brought to the attention of the Company's shareholders (the "**Shareholders**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

NOMINATION OF EXECUTIVE DIRECTORS

In order to strengthen the corporate governance of the Company, following the resignation of Ms. Li, the Board announces that both Dr. CHEN Ze (陳則) ("**Dr. Chen**") and Ms. WU Jingyun (吳菁芸) ("**Ms. Wu**") have been nominated as candidates for executive Directors of the second session of the Board, enlarging the Board to consist of four executive Directors, which shall be subject to consideration and approval by the Shareholders at a general meeting of the Company (the "**General Meeting**").

The biographical details of Dr. Chen and Ms. Wu are as follows:

Dr. Chen, aged 62, joined the Group as the chief scientist in May 2022 and has been serving as a deputy general manager since September 2022. Dr. Chen has nearly 30 years of experience in the fields of virology, pharmaceuticals and biotechnology. From April 1997 to March 2000, he worked as an assistant researcher at the National Institute of Infectious Diseases (國立感染症研究所) in Japan. He then served as a distinguished professor at Hunan Normal University (湖南師範大學) from December 1999 to December 2010, simultaneously working as a Hundred Talents Program researcher at the Wuhan Institute of Virology (中國科學院武漢病毒研究所) from February 2002. From May 2007 to April 2018, he successively served as a researcher, a laboratory director, and then the chief scientist at Shanghai Institute of Biological Products Co., Ltd. (上海生物製品研究所有限責任公司). From April 2018 to November 2021, he served as a deputy general manager at Shanghai Serum Bio-Technology Co., Ltd. (上海賽倫生物技術股份有限公司), a company listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688163). From August 2021 to April 2022, he served as the chief scientist at Hong Kong Biologicals Company Limited (香港生物製品有限公司).

Dr. Chen obtained a bachelor's degree in medicine from Shanghai Second Medical University (上海第二醫科大學) in the PRC in July 1988. He obtained a doctoral (Ph.D.) degree in pathology, immunology and microbiology from the University of Tokyo (東京大學) in March 1997.

The Company will enter into a director service contract with Dr. Chen. The term of office of Dr. Chen as an executive Director shall commence from the date of approval by the General Meeting and shall expire upon the expiration of the term of office of the second session of the Board, subject to re-election upon the expiration of his term of office. Dr. Chen will not receive any Directors' fees for serving as an executive Director of the Company, and will continue to receive remuneration in his capacity as the chief scientist and a deputy general manager of the Company, with a base annual salary of approximately RMB1,500,000, subject to annual bonus, incentives and other income. The remuneration of Dr. Chen is determined by the Board, having regard to the recommendation of the Remuneration and Appraisal Committee of the Board ("**Remuneration and Appraisal Committee**") with reference to the prevailing market situation and his duties and responsibilities to the Group. Details regarding Dr. Chen's remuneration shall be disclosed in the Company's annual report.

Ms. Wu, aged 37, has over 14 years of experience in auditing and accounting. From October 2011 to June 2013, Ms. Wu was a Senior Auditor at PricewaterhouseCoopers Zhong Tian Co., Ltd. (普華永道中天會計師事務所有限公司). From July 2013 to February 2014, Ms. Wu was a Senior Auditor at PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)). From February 2014 to February 2017, she worked at the head office of Shanghai Pudong Development Bank CO., LTD. (上海浦東發展銀行股份有限公司) and was primarily responsible for fund valuation and financial data review across multiple fund types. From March 2017 to March 2021, she served as the manager of the custody operations department of Donghai Securities Co., Ltd. (東海證券股份有限公司). From March 2021 to August 2026, she served as an assistant vice president of BNP Paribas (China) Ltd. (法國巴黎銀行(中國)有限公司).

Ms. Wu obtained her bachelor's degree in accounting and master's degree in business administration, from Shanghai Jiao Tong University (上海交通大學) in the PRC in June 2011 and June 2024, respectively. She has been a member of The Chinese Institute of Certified Public Accountants (中國註冊會計師協會) since January 2014.

The Company will enter into a director service contract with Ms. Wu. The term of office of Ms. Wu as an executive Director shall commence from the date of approval by the General Meeting and shall expire upon the expiration of the term of office of the second session of the Board, subject to re-election upon the expiration of her term of office. Ms. Wu will not receive any Directors' fees for serving as an executive Director of the Company, and will continue to receive remuneration in her capacity as the Chief Financial Officer, with a base annual salary of approximately RMB840,000, subject to annual bonus, incentives and other income. The remuneration of Ms. Wu will ultimately be determined by the Board, having regard to the recommendation of the Remuneration and Appraisal Committee with reference to the prevailing market situation and her duties and responsibilities to the Group. Details regarding Ms. Wu's remuneration shall be disclosed in the Company's annual report.

As at the date of this announcement, Dr. Chen and Ms. Wu do not have any interests in the shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, Dr. Chen and Ms. Wu have confirmed that (i) they did not hold any directorship in other listed companies in Hong Kong or overseas in the last three years; (ii) they do not hold any other positions within the Company and other members of the Group; (iii) they have and had no relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities (the "**Listing Rules**")) of the Company; and (iv) they do not have any other major appointments or professional qualifications.

Save as disclosed in this announcement, as at the date of this announcement, Dr. Chen and Ms. Wu have confirmed that there is no further information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to their appointment that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board believes that the appointments of Dr. Chen and Ms. Wu will strengthen corporate governance and enhance Board diversity. Dr. Chen has extensive experience in the virology, pharmaceuticals and biotechnology industry, together with a long-standing relationship with the Group, which will enable him to contribute to the Board's strategic planning and strengthen oversight of daily operations and internal controls. Ms. Wu's strong background in accounting will support the Group in maintaining a compliant and efficient financial reporting system and in ensuring that the Group's transactions meet regulatory requirements and stakeholder expectations.

The Company will convene the General Meeting to seek approval for the appointment of Dr. Chen and Ms. Wu as executive Directors from the Shareholders.

A circular and notice of the General Meeting containing, among other things, details of the proposed election of executive Directors will be despatched to the Shareholders in due course for the purpose of proposing the above election to the Shareholders for consideration and approval at the General Meeting.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board announces that Ms. Wu has been appointed as the Chief Financial Officer with effect from September 23, 2026. The biographical details of Ms. Wu are set out in the above section titled "NOMINATION OF EXECUTIVE DIRECTORS".

CHANGE OF MEMBERS OF BOARD COMMITTEES

The Board announces that with effect from September 23, 2026, Ms. Li has ceased to act as a member of the Remuneration and Appraisal Committee and a member of the Nomination Committee of the Board (the "**Nomination Committee**"), Mr. HE Yiming (何一鳴) has been appointed as a member of the Remuneration and Appraisal Committee, and Ms. LUI Mei Ka (雷美嘉) has been appointed as a member of the Nomination Committee.

APPOINTMENT OF BOARD SECRETARY AND JOINT COMPANY SECRETARY

The Board announces that Mr. XU Jian (許劍) ("**Mr. Xu**") has been appointed as the board secretary of the Company and a joint company secretary of the Company (the "**Joint Company Secretary**") with effect from September 23, 2026. Ms. LIN Sio Ngo (練少娥) ("**Ms. Lin**"), the existing company secretary who possesses the qualification prescribed under Note 1 to Rule 3.28 of the Listing Rules, will continue to act as the other Joint Company Secretary and will assist Mr. Xu in discharging his duties as a Joint Company Secretary during the Waiver Period (as defined below).

The biographical details of Mr. Xu and Ms. Lin are set out below:

Mr. Xu, aged 42, has over 17 years of experience in securities affairs and board secretarial matters in the pharmaceutical industry. Mr. Xu worked at Sealand Securities Co., Ltd. (國海證券股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000750) from August 2009 to January 2016, and Ping An Securities Co., Ltd. (平安證券股份有限公司) from January 2016 to November 2021, where he was engaged in equity capital markets projects and served as a member of the investment banking division. From November 2021 to December 2025, Mr. Xu served as the board secretary of ChemPartner PharmaTech Co., Ltd. (睿智醫藥科技股份有限公司) ("**ChemPartner**"), a company listed on the Shenzhen Stock Exchange (stock code: 300149), where he was responsible for board secretarial matters, regulatory compliance, information disclosure and investor relations. From December 2025 to August 2026, Mr. Xu served as the vice president of investment development of Shanghai ChemPartner Pharmaceutical Research Group Co., Ltd. (上海睿智醫藥研究集團有限公司), a wholly-owned subsidiary of ChemPartner.

Mr. Xu obtained his bachelor's degree in law and master's degree in law, from Sun Yat-Sen University (中山大學) in the PRC in July 2007 and July 2010, respectively. He also obtained the Board Secretary Qualification Certificate issued by the Shenzhen Stock Exchange in February 2022, and the PRC Legal Professional Qualification Certificate issued by the PRC Ministry of Justice in February 2009.

Ms. Lin is a manager of SWCS Corporate Services Group (Hong Kong) Limited, a professional services provider specializing in corporate services. Ms. Lin has over 20 years of experience in the corporate secretarial and administrative management fields. She has been providing professional corporate services to Hong Kong listed companies as well as private companies. Ms. Lin is currently serving as the company secretary or joint company secretary of several companies listed on the Main Board of the Stock Exchange. Ms. Lin obtained a bachelor's degree in business administration and a master's degree in corporate governance from Hong Kong Metropolitan University in June 2000 and June 2004 respectively. Ms. Lin is an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rules 3.28 and 8.17 of the Listing Rules, the Company must appoint a company secretary who, in the opinion of the Stock Exchange, is capable of discharging the functions of a company secretary by virtue of their academic or professional qualifications or relevant experience.

Although Mr. Xu currently does not possess the formal qualifications of a company secretary as required under Rule 3.28 of the Listing Rules, having considered Mr. Xu's professional knowledge and experience as indicated in his biographical details above, the Board considers that Mr. Xu is capable of discharging the functions of the Joint Company Secretary. The Company has applied for, and the Stock Exchange has granted the Company, a waiver (the "**Waiver**") from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the date of Mr. Xu's appointment as the Joint Company Secretary (the "**Waiver Period**") on the conditions that (i) Mr. Xu must be assisted by Ms. Lin, who possesses the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules, during the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Mr. Xu, having had the benefit of Ms. Lin's assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 such that a further waiver will not be necessary. The Waiver applies to Mr. Xu's appointment as the Joint Company Secretary only and may be withdrawn or changed if the Company's situation changes.

CHANGE OF AUTHORIZED REPRESENTATIVE

The Board announces that Ms. Li has ceased to be an authorized representative of the Company under Rule 3.05 of the Listing Rules (the "**Authorized Representative**") upon her resignation as an executive Director, and Mr. Xu has, in place of Ms. Li, been appointed to act as the Authorized Representative, both with effect from September 23, 2026.

CONTINUED SUSPENSION OF TRADING

Trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, September 23, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai and Mr. HE Yiming as executive Directors; (ii) Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun, Mr. CHEN Chengbei and Ms. LUI Mei Ka as independent non-executive Directors.